Another Reason To Watch Kite's CAR-T Results At ASH
This article was originally published in The Pink Sheet Daily
Belldegrun assures the patient death in an ongoing Phase I trial was not related to KTE-C19; further details will be presented at American Society of Hematology meeting in December.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.